Four nonvolatile nerve agent surrogates, 4-nitrophenyl ethyl dimethylphosphoramidate (NEDPA, a tabun surrogate), 4-nitrophenyl ethyl methylphosphonate (NEMP, a VX surrogate), and two sarin surrogates, phthalimidyl isopropyl methylphosphonate (PIMP) and 4-nitrophenyl isopropyl methylphosphonate (NIMP), were synthesized and tested as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors. These surrogates were designed to phosphorylate cholinesterases with the same moiety as their respective nerve agents, making them highly relevant for the study of cholinesterase reactivators. Surrogates were characterized by liquid chromatography-mass spectrometry and nuclear magnetic resonance. NEMP, PIMP, and NIMP were potent inhibitors of rat brain, skeletal muscle, diaphragm, and serum AChE as well as human erythrocyte AChE and serum BuChE in vitro. PIMP was determined to degrade quickly in aqueous solution, making it useful for in vitro assays only, and NEDPA was not a potent inhibitor of AChE or BuChE in vitro; therefore, these two surrogates were not tested in subsequent in vivo studies. Sublethal dosages (yielding about 80% brain AChE inhibition) were determined for both the stable sarin surrogate, NIMP (0.325 mg/kg ip), and the VX surrogate, NEMP (0.4 mg/kg ip), in adult male rats. Time course studies indicated the time to peak brain AChE inhibition for both NIMP and NEMP to be 1 h postexposure. Both surrogates yielded severe cholinergic signs. These dosages did not require the addition of atropine to prevent lethality, and the rate of AChE aging was slow, making these surrogates useful for reactivation studies both in vitro and in vivo. The surrogates synthesized in this study are potent yet safer to test than nerve agents and are useful tools for initial screening of nerve agent oxime therapeutics.
The synthesis of organophosphate (OP) compounds as potential insecticides during the early 1940s led to the discovery of several extremely toxic compounds (Johnson et al., 2009) . The volatility and toxicity associated with these OPs made them impractical for insecticide applications but appealing as chemical warfare agents (Tucker, 2006) . The main mechanism of toxic action for these OPs is the inhibition of the serine hydrolase acetylcholinesterase (AChE) in synapses and neuromuscular junctions, which results in an accumulation of the neurotransmitter acetylcholine and ultimately hyperstimulation of the nervous system resulting in loss of consciousness, seizures, apnea, and death from respiratory failure (Ecobichon, 2001) . The nerve agents range in acute toxicity levels, but all are extremely toxic and can result in rapid death of mammals (Agency for Toxic Substances and Disease Registry, 2011) .
Three nerve agents that were synthesized, produced in large amounts, and stockpiled during World War II or shortly thereafter were tabun (ethyl dimethylphosphoramidocyanidate; GA), sarin (isopropyl methylphosphonofluoridate; GB), and VX (S-2-diisopropylaminoethyl O-ethyl methylphosphonothioate) (Tucker, 2006) . These compounds are considered to be some of the greatest chemical threat agents to the warfighter or to civilians during a terrorist attack, such as the one that occurred in the subway system in Tokyo, Japan, in 1995 (Suzuki et al., 1995) . Because of the significant hazards associated with these nerve agents, they can be tested only in authorized laboratory facilities; therefore, much of the research for therapeutics for nerve agents must be conducted using less dangerous surrogates, such as diisopropyl fluorophosphate (DFP) that phosphorylate AChE with different moieties than the nerve agents. In addition, surrogates should also reflect the extent of AChE-OP adduct ''aging'' that occurs following modification of AChE by their corresponding nerve agents. Aging is the nonenzymatic process by which an alkyl group from the OP adduct is removed, thus yielding a negatively charged phosphonyl adduct on the active site serine residue (Ecobichon, 2001) .
The current investigation synthesized and tested OPs that can serve as nerve agent surrogates and that are more relevant than most other surrogates, such as DFP or paraoxon. The OPs described here phosphorylate AChE with the same moiety as the actual nerve agents, but they are not volatile and therefore can be tested in facilities not authorized for nerve agent testing. Surrogates for the nerve agents tabun, sarin, and VX were synthesized: 4-nitrophenyl ethyl dimethylphosphoramidate (NEDPA), a tabun surrogate; 4-nitrophenyl ethyl methylphosphonate (NEMP), a VX surrogate; and two sarin surrogates, phthalimidyl isopropyl methylphosphonate (PIMP) and 4-nitrophenyl isopropyl methylphosphonate (NIMP) (Fig. 1) . Ohta et al. (2006) described the synthesis of the NIMP surrogate of sarin after synthesizing other nerve agent surrogates, bis-isopropyl methylphosphonate and bis-pinacolyl methylphosphonate, that were very toxic and unstable (Nagao et al., 1997; Niijima et al., 1998) . The NIMP was safer to synthesize and provided good AChE inhibition for reactivation studies. This surrogate, NIMP, which was previously described by others, along with the three new surrogates synthesized in our study will be beneficial for the testing of potential reactivators for nerve agent-inhibited AChE. In this paper, we describe the synthesis, chemical characterization, and biological potencies of these OP surrogates. Several rat tissues were studied in vitro and rats were used for in vivo tests. Bovine brain was used as a convenient source of AChE for aging studies, and guinea pig brain was studied because of the frequent use of this species in nerve agent therapeutic testing. Human AChE and butyrylcholinesterase (BuChE) were also assayed.
MATERIALS AND METHODS

Chemicals
All OPs were synthesized from commercially available intermediates, and all reagent grade chemicals were purchased from Sigma Chemical Co. (St Louis, MO) or ThermoFisher Scientific (Waltham, MA).
Synthesis of Nerve Agent Surrogates
Reaction 1: Nitrophenyl Ester Homologs
General reaction (NIMP and NEMP) ( Fig. 2A ). Methylphosphonic dichloride (1.59 g, 12 mmol) and 4-nitrophenol (1.39 g, 10 mmol) were stirred in benzene (80 ml) at room temperature. Triethylamine (1.4 ml, 10 mmol) in benzene (20 ml) was added slowly and the mixture was stirred at room temperature for 2 h. The appropriate alcohol, 2-propanol or ethanol (20 mmol) for NIMP or NEMP, respectively, and triethylamine (20 mmol) in benzene (20 ml) were added slowly and the mixture was stirred at room temperature for an additional 3-4 h.
For purification, the reaction mixtures were filtered and washed with 2% aqueous sodium bicarbonate. The benzene phase was dried over anhydrous sodium sulfate and evaporated on a rotary evaporator. The yellow liquid product was dissolved in hot hexane and chilled at À16°C overnight. All final products were pale yellow liquids that chromatographed as one major and one to two minor spots on thin layer chromatography. The most common minor impurity was 4-nitrophenol.
Reaction 2: General Reaction (NEDPA)
The procedure was the same as described above except that the final product was recrystallized from hexane ( Fig. 2B ).
Reaction 3: Phthalimidyl Ester Homolog (PIMP)
The procedure was the same as for the 4-nitrophenol homolog above except for the replacement of the 4-nitrophenol with N-hydroxyphthalimide (Fig. 2C) .
Because of decreased stability of PIMP, the sodium bicarbonate wash was omitted from the workup. The product was a solid and could be purified by recrystallization from hexane.
Surrogate Characterization Methods
Liquid Chromatography-Mass Spectrometry Analysis
Electrospray ionization mass spectral analyses of the surrogates were performed on a Thermo Quantum Access Max triple stage quadrupole mass spectrometer. Liquid chromatography/electrospray ionization/mass spectrometry (LC-ESI-MS) experiments were accomplished using an attached Waters Acquity Ultra Performance Liquid Chromatography System. The mobile phase for the chromatography was a blend of solvent A (0.1% vol/vol acetic acid in water) and solvent B (0.1% vol/vol acetic acid in methanol). A solution of the sample (3 ll, 200lM in methanol) was injected onto an Acquity UPLC BEH C18 column (2.1 3 100 mm, 1.7 lm) equipped with a VanGuard precolumn (2.1 3 5 mm, 1.7 lm) and eluted at 0.3 ml/min using the following program: 0 min (85% A, 15% B), 0.75 min (85% A, 15% B), 1.5 min (70% A, 30% B), 3.5 min (53% A, 47% B), 5 min (46% A, 54% B), 6 min (45% A, 55% B), 10.5 min (40% A, 60% B), 15 min (30% A, 70% B), 16 min (20% A, 80% B), 17 min (0% A, 100% B), 19 min (0% A, 100% B), 20 min (85% A, 15% B), and 21 min (85% A, 15% B). The entire column eluate was directed to an ultraviolet (UV) detector (set to a wavelength of 254 nm) and then to the mass spectrometer (in the positive ion mode). The UV absorbance and relative total ion abundance (m/z ¼ 100-600) were measured throughout the chromatographic run. Solvent blank samples (water) were run between the surrogates to ensure there was no carryover between samples. The source settings were as follows: spray voltage, þ3000 V; vaporizer temperature, 37°C; capillary temperature, 270°C; sheath gas pressure, 40 psi; and auxiliary gas pressure, 20 psi. 
Nuclear Magnetic Resonance Analysis
Animals
Adult male Sprague Dawley-derived rats (250-300 g) were housed in an AAALAC-accredited facility in a temperature-controlled environment (22 ± 2°C) with a 12-h dark-light cycle with lights on between 0700 and 1900 h. LabDiet rodent chow and tap water were provided ad libitum. The Mississippi State University Animal Care and Use Committee and the Defense Threat Reduction Agency Animal Care and Use Committee approved all procedures. Bovine brain was obtained from an abattoir. Frozen guinea pig brains were provided by Dr Tom Snider, Battelle (Columbus, OH).
In Vitro AChE median inhibitory concentration Determination
For in vitro median inhibitory concentration (IC 50 ) determination, brain, skeletal muscle, diaphragm, and blood were collected from naïve rats. The solid tissues were immediately snap frozen in liquid nitrogen and stored at À80°C. The serum was prepared by centrifuging clotted blood at 10,000 3 g for 8 min; the serum was decanted off and was stored at À80°C.
AChE activities were determined using a discontinuous spectrophotometric assay (modification of Ellman et al., 1961) with acetylthiocholine as the substrate and 5,5#-dithio-bisnitrobenzoic acid (DTNB) as the chromogen (Chambers et al., 1988) . Pooled tissues from five rats were homogenized in 0.05M Tris-HCl (pH 7.4, 25°C) using a tissue homogenizer. Tissue concentrations in the assay were as follows: rat brain 1 mg/ml, rat skeletal muscle 5 mg/ml, rat diaphragm 5 mg/ml, and rat serum 2.5 ll/ml. Guinea pig brain was assayed at 1.25 mg/ml. Bovine brain was assayed at 2 mg/ml.
Tissue homogenates were incubated with ethanol vehicle or five concentrations of each OP in ethanol vehicle (10 ll stock solution/ml homogenate) at 37°C for 15 min in 0.05M Tris-HCl buffer, pH 7.4 at 25°C (2 ml total assay volume). Following the initial incubation, acetylthiocholine (1mM) was added as a substrate and incubation continued for an additional 15 min. The reaction was terminated and color was developed using 250 ll of a 5% SDS/DTNB mixture (4:1). Absorbance was measured at 412 nm. Eserine sulfate (10lM) was incubated with a subset of control samples to correct for nonenzymatic hydrolysis. Percent inhibition of control (ethanol vehicle) absorbance was calculated for each concentration. IC 50 values were determined by linear regression analysis of the plot of the logit of the percent inhibition versus log 10 OP concentration. The best-fit line was drawn using points corresponding to the 20-80% inhibition range, and the equation of the best-fit line was solved for the x-intercept. The procedure was the same for all tissues except for serum, which included iso-OMPA (tetraisopropyl pyrophosphoramide) (10lM) to inhibit carboxylesterase and BuChE.
In Vitro Human AChE and BuChE IC 50 Determination Pooled human erythrocyte AChE was purchased from Sigma Chemical Co. and diluted to 7.5 mU/ml in 0.1M Tris-HCl (pH 7.4, 25°C) and assayed as described above to determine AChE IC 50 s. In addition, IC 50 s for human serum BuChE were determined from pooled human serum purchased from Sigma Chemical Co. Briefly, serum was diluted to 1.5 ll/ml in 0.1M Tris-HCl (pH 7.4, 25°C) and assayed as described above except that butyrylthiocholine (1mM) was used as the substrate.
In Vitro AChE Aging Determination
Bovine brain homogenate (50 mg/ml) was incubated for 15 min (our standard incubation time) or 60 min later at 75 min at 37°C with the sarin surrogate PIMP at a concentration (500nM) that yielded about 80% AChE inhibition or EtOH vehicle. PIMP degrades quickly in aqueous solution preventing reinhibition of reactivated AChE. Subsequently, samples were incubated for 30 min with 100mM 2-pyridine aldoxime methiodide (2-PAM; an oxime AChE reactivator) in a 1:1 DMSO/EtOH vehicle or vehicle only. Samples were diluted 25-fold and AChE activity was determined by the spectrophotometric assay described above. Percent of AChE aged was calculated as the decrease in reactivation by 2-PAM after 75 min versus that after 15 min.
In Vivo AChE Inhibition Determination
Rats were administered ip the surrogate OP (in DMSO vehicle for fast absorption and consistent response; NIMP 0.325 mg/kg or NEMP 0.4 mg/kg); these dosages were determined to inhibit approximately 80% brain AChE at time of peak inhibition. Additional control rats were administered the vehicle (DMSO) ip. Rats were sacrificed at 30, 60, 120, or 240 min or 24 h to determine the time course of inhibition of AChE for the two surrogates in brain, blood, and diaphragm. Rats were observed for signs of cholinergic toxicity.
Brain and diaphragm samples were homogenized and assayed at a concentration of 1 or 5 mg/ml, respectively, in Tris-HCl (0.05M, pH 7.4 at 25°C) as described above. Blood was collected with EDTA as an anticoagulant and was centrifuged at 3000 3 g for 10 min to separate plasma and erythrocytes, which were then diluted in sodium phosphate buffer (0.1M, pH 8.0 at 25°C) to 0.001 and 0.0005 ll/ml, respectively, and assayed as described above. Protein concentration was determined for all tissue samples using the Folin phenol reagent according to the method of Lowry et al. (1951) . The AChE activity was calculated as nanomoles per minute per microgram protein, and percent inhibition was calculated by comparison of the activities of the corresponding vehicle control animals and NIMP-or NEMP-treated animals.
In Vivo AChE Aging Determination
Brain homogenates, 40 mg/ml, from control and surrogate-treated animals were incubated with and without 100lM of the oxime AChE reactivator 1,1#-trimethylene bis(4-formyl-pyridinium bromide)dioxime (TMB-4) for 60 min (Chambers and Chambers, 1989) . Samples were diluted to 1 mg/ml and AChE activity was determined spectrophotometrically as described above. Aging was calculated as percent of inhibited AChE not reactivated by TMB-4. Percent aging was determined at 1, 2, 4, and 24 h posttreatment.
Statistics
Data were analyzed using SigmaStat software on a PC. For all experiments, data were analyzed by ANOVA and significant difference among groups being determined using Tukey's post hoc test with significance p 0.05.
RESULTS
Synthesis of Surrogates
The nerve agent surrogates PIMP, NIMP, NEMP, and NEDPA were synthesized with structures confirmed by LC-MS, and purity determined by 1 H NMR to be 91.4, 88.9, 69.4, and 83.1%, respectively. The purity of NEMP was lower than 528 MEEK ET AL. expected; however, the major impurity identified by NMR, bis-ethyl methanesulfonate (14.2%), was not expected to be a potent AChE inhibitor because it lacks a suitable leaving group. No adjustment of concentrations for purity was made for the surrogates (additional purity data is provided as Supplementary data).
In Vitro Characterization
AChE IC 50 s. AChE inhibition curves for each of the surrogates were determined, and the IC 50 s were calculated as indices of potency (Table 1 ). The inhibitory potency of both the sarin surrogates, PIMP and NIMP, and the VX surrogate, NEMP, were in the nanomolar range for rat, bovine, and guinea pig brain, with the potency greatest for rat brain followed by bovine and guinea pig. NEMP was the most potent surrogate of the four tested in all species and tissues. Potency of the tabun surrogate, NEDPA, was in the micromolar range; therefore, it would not be useful for reactivation studies and was not included in subsequent in vivo testing. The potency of the surrogates within rat tissues was highest for brain but was similar for peripheral tissues, with serum being the only tissue significantly less sensitive. The potency of the surrogates against human erythrocyte AChE was similar to those determined for the rat, with NEMP being the most potent. The surrogates were less potent inhibitors of human serum BuChE, with the exception of the sarin surrogate, PIMP.
In Vitro Aging of Surrogates
AChE aging was determined for PIMP, NIMP, and NEMP in vitro using bovine brain. Only slight aging was observed during a 60 min period with PIMP (17%) or NIMP (16%). No aging had occurred during the 60-min incubation period with NEMP. Aging studies were not conducted on NEDPA because of its poor AChE inhibitory potency.
In Vivo Studies
To prepare for future antidotal reactivator screening, experiments were designed to determine high sublethal dosages that would yield about 80% brain AChE inhibition without concurrent administration of atropine. Dosages that resulted in > 90% brain AChE inhibition resulted in mortality, which we wanted to avoid because determining LD 50 s was not the purpose of this study. The target dosages from dose-response curves for the sarin surrogate, NIMP, and the VX surrogate, NEMP, were determined to be 0.325 and 0.4 mg/kg, respectively. Time course studies determined the peak brain AChE inhibition time to be 60 min postinjection for both NIMP and NEMP (Figs. 3A and 4A) . Signs of cholinergic poisoning were evident in all rats administered NIMP and NEMP by 15 min and included chewing, facial twitches, teeth chatter, and head tremors. These signs progressed between 15 and 60 min to severe muscle fasciculations, clonus, convulsions, and respiratory distress. The signs were consistent with the brain AChE inhibition time course. Brain AChE inhibition slowly decreased following the peak of 1 h for both NIMP and NEMP to 65 and 40%, respectively, at 24 h (Figs. 3A and 4A). Signs of cholinergic distress had diminished by 24 h. Inhibition of ChE in diaphragm, plasma, and erythrocytes followed a similar pattern to the brain AChE inhibition, recovering significantly at 24 h (Figs. 3 and 4) . Surrogateinhibited brain AChE showed no appreciable aging until 24 h postexposure and was still low for NEMP (Table 2) , this was reflected in the lower AChE recovery in the NIMP-treated samples.
DISCUSSION
The synthesis of highly relevant nonvolatile nerve agent surrogates that are potent inhibitors of AChE allows for more laboratories not authorized for nerve agent testing to conduct studies that may lead to the development of new AChE reactivators. The synthesis described in this study is similar to the synthesis of a sarin surrogate described by Ohta et al. (2006) , which achieved the same product, NIMP. The synthesis can be accomplished with commercially available intermediates and standard chemical synthesis procedures. The surrogates PIMP, NIMP, NEMP, and NEDPA were designed to mimic the action of three of the most important nerve agents, sarin, VX, and tabun, by leaving AChE phosphorylated with the same moiety as actual nerve agents by substituting the presumed leaving group for each nerve agent. Other surrogates have been synthesized that substituted thiocholine for the fluorine or cyanide on the central phosphate of nerve agents and were found to leave human BuChE phosphorylated with the same adduct as sarin and soman (Gilley et al., 2009) . Surrogates with a fluorescent 3-chloro-7-oxy-4-methylcoumarin leaving group have also been synthesized for screening enzymes for nerve agent hydrolase activity (Briseno-Roa et al., 2006) . The sarin and VX surrogates synthesized in this study were tested and determined to be potent inhibitors of AChE in vitro and were very similar in potency to the NIMP sarin surrogate synthesized by Ohta et al. (2006) . While the purity of the surrogates, especially NEMP, was not as high as was anticipated and would require further cleanup procedures to achieve the desired purity of over 90%, the impurities that were identified (included in Supplementary data) would have little to no AChE inhibitory potential. Therefore, we expect the potency would increase with greater purity of the surrogates. Surprisingly, the tabun surrogate, NEDPA, was determined to not be a potent inhibitor of AChE; however, because there are two groups that can serve as leaving groups for tabun (Briseno-Roa et al., 2006) , substitution of the cyano group may have substantially reduced the reactivity of NEDPA compared with tabun. AChE IC 50 s for brain tissue have been shown to be good predictors of lethality of nerve agents (Fawcett et al., 2009) . The IC 50 s for surrogates PIMP, NIMP, and NEMP were all in the nanomolar range and were only slightly higher than the reported IC 50 s for their corresponding nerve agents (Fawcett et al., 2009) . This is consistent with the reported lethality of the nerve agents, with VX (rat iv LD 50 7-10 lg/kg) being more potent than sarin (rat iv LD 50 45-63 lg/kg) (John et al., 2009) . With the phosphorylation moiety of NIMP and NEMP being the same as their respective nerve agents and the in vitro potency of NEMP slightly greater than NIMP, it was anticipated that the in vivo potencies for the two surrogates would be similar; however, the dosage resulting in equivalent rat brain AChE inhibition was slightly higher for NEMP than NIMP. This difference may be attributed to both the differences in the purity of the surrogates and the ability of the surrogates to cross the blood-brain barrier (BBB), as has been reported for VX and sarin, with VX being protonated and therefore positively charged, reducing its ability to cross the BBB compared with sarin (Fawcett et al., 2009) . In addition, the efficacy of OP stoichiometric detoxication enzymes, such as BuChE and carboxylesterase, may be different between the surrogates and could contribute to the differences observed in vivo (Chambers and Chambers, 1990; Maxwell, 1992) . Unlike humans (Li et al., 2005) , rats have carboxylesterase in the plasma increasing the likelihood of detoxication of an OP anticholinesterase before it reaches the target AChE; the efficacy of these carboxylesterases in stoichiometric detoxication may be different among the surrogates (Chambers et al., 2010) . In addition, the catalytic detoxication of nerve agents by paraoxonase, an enzyme that can hydrolyze a variety of esters and lactones, occurs at different efficiencies among the nerve agents and may also contribute to the differences in potency of these surrogates in vivo (Davies et al., 1996) . The anticholinesterase activity of these nerve agent surrogates is sufficient to mimic nerve agent exposure resulting in typical signs of cholinergic poisoning; however, atropine was not required for survival. Increasing the dosage of the surrogates would most likely require the addition of an antidote, i.e., atropine, to prevent lethality as the signs of cholinergic poisoning were severe with the dosages used in this study. The rate of aging of surrogate-bound AChE was similar to reported nerve agent-bound AChE, with the sarin adduct aging faster than VX (Milatovic and Jokanovic, 2009 ). As with sarin-and VX-modified cholinesterase enzymes, the surrogatemodified enzymes aged relatively slowly, allowing a window of opportunity for reactivation by oximes. However, for the sarin surrogate, significant aging (about 70% in the brain) was observed at 24 h postexposure, illustrating the need to administer a reactivator soon after exposure to the surrogate to achieve maximum therapeutic efficacy. The potency and rate of aging of these nerve agent surrogates make them useful for reactivation studies both in vitro and in vivo. These reactivation studies are currently being conducted in our laboratories to determine the efficacy of a series of novel oximes as potential therapeutics. The surrogates synthesized and tested in this study provide safer yet highly relevant tools for initial screening of oximes as therapeutics for nerve agents.
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